AMP activated protein kinase (AMPK) is a critical energy sensor, regulating signaling networks involved in pathology including metabolic diseases and cancer. This increasingly recognized role of AMPK has prompted tremendous research efforts to develop new pharmacological AMPK activators. To precisely study the role of AMPK, and the specificity and activity of AMPK activators in cellular models, genetic AMPK inactivating tools are required. We report here methods for genetic inactivation of AMPK 1/ 2 catalytic subunits in human cell lines by the CRISPR/Cas9 technology, a recent breakthrough technique for genome editing.
Introduction

CRISPR/Cas9 genome-editing system
The rapid development of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/ CRISPR associated protein 9 endonuclease (Cas9) technology provides unprecedented genomic research tools. CRISPR are short DNA sequences found in bacteria.
Together with the bacterial Cas9 these sequences are involved in the clearance of foreign DNA from bacteria [1] . Shortly after its discovery, the CRISPR/Cas9 system has been engineered for genome editing including in eukaryotic cells. Indeed, CRISPR/Cas9 offers a specific genomic tool based on the complementation of genomic DNA by a 20-mer 3 oligonucleotide sequence followed by a consensus sequence called PAM for protospacer adjacent motif. This guide RNA (sgRNA) allows the recruitment of Cas9 to the targeted genomic DNA sequence leading to DNA double strand breaks (DSB). In case of DSB repair by non homologous end joining (NHEJ), small insertions/deletions within coding sequences may be produced leading to a premature stop codon [2, 3] . Alternatively, DSB may be repaired by homologous recombination (HR), which may be exploited for targeted mutagenesis of endogenous genes when using a mutated recombination template [4] . In fact, multiple refinements of the CRISPR/Cas9 technology have been described and the power of these techniques as well as their potential applications is increasingly growing.
Why and how disrupting AMPK activity?
AMP-activated protein kinase (AMPK) is one of the main cellular energy sensor, activated by the binding of AMP or ADP to its γ-regulatory subunit and by the phosphorylation of its αcatalytic subunit [5] . Once activated, AMPK modifies cell metabolism (inhibition of anabolism and activation of catabolism) to restore cellular energy balance. Tremendous research efforts are therefore ongoing to efficiently activate AMPK in the context of metabolic diseases or cancer [5] . Abrogating AMPK activity may help to define the role of AMPK in a given cellular context. Unfortunately, no specific AMPK inhibitors are currently available and genetic knockdown/knockout approaches are recommended to validate the function of AMPK (see Chapter 12) . Hence, specific deletion of AMPK genes represents an invaluable tool to assess the specificity of AMPK-targeting small molecules (mostly AMPK activators). While targeting regulatory AMPKβ or γ subunits may be important to disrupt the regulation of AMPK activity and function, AMPKα gene inactivation is sufficient to abrogate AMPK serine/threonine kinase activity [6] . At first glance, we used RNA interference (RNAi) by small hairpin RNA (shRNA) to deplete AMPKα from acute myeloid leukemia (AML) 4 cells as done by other groups in other cellular contexts [7] [8] [9] . However, we failed to achieve a complete inhibition of AMPKα, with a residual expression of 10-20% at the protein level [10] .
Indeed, Saito and colleagues recently demonstrated the essential pro-survival function of AMPK in AML cells exposed to stress [11] , thus explaining the negative selection of cells with efficient AMPK1 knockdown. Hence, efficient and stable AMPK knockout in human cell lines represents a challenge. To avoid this limitation, and also to reduce the probability of off-target as observed with shRNA [12] , we moved towards a CRISPR/Cas9-based approach to study AMPK function in human cell lines. In this chapter, we describe the use of CRISPR/Cas9 technology to disrupt AMPKα MOLM-14 and OCI-AML3 cells, and concomitant AMPKα α2 expression in colon carcinoma Caco2 cells that may provide invaluable tools for further studies on AMPK biology and development of specific AMPK activators for the treatment of cancer and metabolic diseases. We attempted to find common DNA sequences across PRKAA1 and PRKAA2 genes (encoding the AMPK1 and AMPK2 catalytic subunits, respectively) for targeting by a single sgRNA, but no such sequence was available within PRKAA1 or PRKAA2 coding or non-coding DNA. While multiplexing sgRNA into a single vector is possible [13] , we used a sequential procedure to achieve first AMPKα1 and then AMPKα2 knockdown in single-cell clones. We thus developed PRKAA1-and PRKAA2-targeting CRISPR/Cas9 systems allowing a convenient sequential selection of AMPKα -depleted single cell clones based on antibiotic resistance, and then isolation of AMPKα2 knockout single-cell clones based on the expression of a fluorescent marker. In particular, we describe procedures to design AMPKα α2 targeting sgRNAs, and cloning into lentiviral vector. We also provide methods for infection, clonal selection, screening and validation of single-cell CRISPR clones.
Sequencing
Sequencing primers:
-PRKAA1 primers: forward 5'-ATCACCAGGATCCTTTGGCA-3' and reverse 5'-TGCTTTCCTTACACCTTGGTG-3'.
-PRKAA2 primers: forward 5'-GCTGCACTGTGGGTAGGC-3' and reverse 5'- 
Methods
sgRNA design and cloning
Putative target sites can be identified by simply scanning the region of the particular genomic location that you want to target (but you should check your sgRNA design for potential offtarget effects) or by using online bioinformatical tools dedicated to sgRNA design. (See note 3).
Human AMPKα catalytic subunit encompasses two isoforms, AMPKα1 and AMPKα2, encoded by the PRKAA1 and PRKAA2 genes located at chromosomes 5p13.1 and 1p32.2, respectively. PRKAA1 is made of 9 exons ( Figure 1A ) representing 5088 base pairs (bp), and encodes a 559 aminoacids (AA) protein of 64 kDa. PRKAA2 coding sequence is 9280 bp-long but with a long 3' untranslated region, and encodes a 552 AA protein of 62 kDa ( Figure 1B ).
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To target PRKAA1 gene, we designed 2 sgRNAs targeting PRKAA1 exon 7. To target PRKAA2 gene, we designed 2 sgRNAs targeting PRKAA2 exon 1 ( Figure 1A and B).
[ Figure 1 near here] [ Figure 2 near here]
Lentivirus production
To produce recombinant lentivirus, HEK293-T packaging cells are transfected with the packaging plasmids pVSVg and psPAX2 encoding lentiviral proteins (Gag, Pol and Env) and the transfer plentiCRISPR/ sg RNA plasmid. We propose here two different methods for lentiviral particles production using HEK293T packaging cells. ( 
Cell infection and clonal isolation
Determination of MOI
The volume of supernatants used for infection may vary for each cell line and depends on lentiviral titer. Determination of the multiplicity of infection (MOI) for each cell line is recommended and is valid only for a given lentiviral supernatant batch [14] . To ensure that most cells receive only one stably-integrated sgRNA, a MOI of 0.3 should be used. (See note 18).
MOI theoretically is the number of viral particles per cell, a MOI of 1 meaning that 1 particle reached a single cell. However, particles may not lead to viral genome integration in all cases and transduction is not linear but follows a Poisson distribution considering that each event is independent. MOI can be determined by using the following formula:
where m = MOI and P = probability of infection. [ Figure 3 near here] [ Figure 4 near here]
Screening and validation
Validation of genetic modification by Sanger sequencing 75. Use non-fluorescent primers to generate amplicons as described above (steps 68-70).
76. Sequence the amplicons by using the same primers. Representative chromatograms are provided in Figure 4C (right panel) for correlation with fragment analysis for the same clone.
Verification of knockout cell clones by immunoblotting analysis
After validation of sequence perturbation, Western blot analysis is recommended for verifying protein expression of targeted genes (See note 24). Methods for performing Western blot are described in Chapters 24 and 27.
Western blots from CRISPR/AMPK1-modified MOLM-14-and OCI-AML3-derived clones are shown in Figures 5A-C. Western blots from CRISPR/AMPK1-and CRISPR/AMPK2modified Caco2-derived clones are shown in Figure 3A and B.
[ Figure 5 near here]
Notes
1. Although we provide a comprehensive view of CRISPR/Cas9 use in human AML and colon carcinoma cell lines, the methods described here may be applied to AMPK knockdown in other human cell lines as well as to any gene of interest.
2. Recent breakthrough allows researchers to disrupt the expression of a given gene by multiple means. Among the most popular techniques are RNA interference and CRISPR/Cas9, whose pros and cons are reviewed by other [12] . While both techniques might be used to achieve a partial knockdown of protein expression (for example with inactivated dCas9 fused to transcriptional modulators [15] ), only CRISPR/Cas9 can achieve a complete and stable inhibition of protein expression. We believe that most of the technical pitfalls in CRISPR/Cas9 assays could be overcome after a careful adaptation of our current canvas to each cell type and sgRNAs, providing an invaluable tool for AMPK pharmacological research and beyond.
3. Many bioinformatics tools are available online to help in the design of sgRNA (e.g., ZiFit, CRISPR Design Tool). We used the optimized CRISPR Design application software from Dr Feng Zhang's laboratory (http://crispr.mit.edu). This software provides an accurate analysis of off-target sites. Due to the growing use of the CRISPR/Cas9 technology, more and more sgRNA sequences will be published to target a given gene/protein. Thus, it will be possible to pick-up already validated sgRNA sequences into published articles. Some companies also offers ready-to-use plasmids containing a validated sgRNA and also services for lentiviral particle production for a given plasmid that may represents a valuable assets, particularly for teams with limited experience with the CRISPR/Cas9 technology.
4.
In previous publication, we have used the lentiCRISPRv1 plasmid [10] , formerly referenced under the Addgene reference #49545, but this plasmid is currently not available due to the recent development of lentiCRISPRv2 plasmid (Addgene reference #52961). lentiCRISPRv2 is identical to the original lentiCRISPRv1 but produces nearly 10-fold higher titer virus. 3'-CXXXXXXXXXXXXXXXXXXXXCAAAA-5' 11. A control sgRNA that does not match any genomic sequence can be also synthesized.
We mostly used the
We used the following non-targeted guide as a control: 5'-
12. We suggest using two (or more) different sgRNA sequences for each target gene, to be able to conclude that the observed effects are directly due to gene knockout, rather than to off-target activities of the constructs.
13. If phosphorylated oligonucleotides are ordered, the use of T4 PNK is omitted.
14.
In order to minimize the risk of self-ligation of the plentiCRISPR plasmid, an additional digestion with 30 U of NsiI in the presence of 3 U of thermosensitive alkaline phosphatase (FastAP, EF0651, Thermo Scientific) is performed.
Lentiviral transfer plasmids contain Long-Terminal Repeats (LTRs) and must be
transformed into recombination-deficient bacteria. We use Stbl3 E. coli (ThermoFisher scientific, C7373-03) although other RecAstrains may be used as well.
The choice between calcium/HBS and lipofectamine TM 2000 to transduce HEK293
cells is mostly based on the cost/efficiency balance. For large lentiviral productions, we generally use calcium/HBS transductions for cost/efficiency reasons. In case of hard-to-transduce cell line, filtrated and concentrated supernatants should be used in priority. Alternatively, lentiviral production can be delegated to commercial companies. Lentiviral supernatants should be stored at -80°C and freezing/thawing cycles should be avoided by aliquoting the supernatants in small fractions.
Lentivirus supernantants can be concentrated by ultracentrifugation to increase
transduction efficiency that may be helpful for some cell types. Concentration of lentivirus is achieved through centrifugation in a SW32Ti rotor at 22 000 rpm for 1h30 with the following settings: acceleration 3; deceleration 3. Concentrated supernatants are then stored at -80°C.
18. Researchers should be aware that lentiviral transduction efficacy is widely different across cell line, and that each lentiviral supernatant batch also produces different transduction rates for the same cell line. We recommend the determination of a MOI 22. In our experience, the probability of inducing DNA alterations by CRISPR/Cas9 is variable depending on the vector, sgRNA and cell line. Therefore, achieving a significant depletion of a target protein on a bulk cellular population by this method is uncommon. In MOLM-14 and OCI-AML3 bulk populations, efficient AMPKα1 knockdown is achieved using AMPK#2 sgRNA but AMPKα1 protein expression is barely affected by AMPK#1 sgRNA in these cells ( Figure 3A) . We may extrapolate the probability of efficient knockdown, as in OCI-AML3 cells, 2/12 (16%) clones
were AMPKα1-depleted with AMPK#1 guide and 7/12 (58%) with AMPK#2 guide ( Figure 3B ). Similar, we found 1/5 (20%) modified clones with AMPK#1 and 5/7 (71%) with AMPK#2 in the MOLM-14 cell line ( Figure 3C ). We thus suggest performing a single-cell selection of cellular clones that will be further genetically characterized.
23. We have developed an easy-to-use assay to amplify a region avoiding DNA extraction, 
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